TransMedics Group, Inc. Common Stock
TMDX
$72.92
-23.19%
TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy for end-stage organ failure patients. It has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring platform designed to preserve donor organs in a near-physiologic state, addressing the limitations of traditional cold storage. The company is a clear technology leader and disruptor in the organ preservation segment of the medical device industry. The current investor narrative centers on its transition to a profitable, high-growth commercial entity, as evidenced by its recent surge in revenue and net income, though recent stock price volatility reflects debates over its valuation and growth sustainability following a significant run-up.…
TMDX
TransMedics Group, Inc. Common Stock
$72.92
Investment Opinion: Should I buy TMDX Today?
Rating & Thesis: Hold. TMDX is a compelling but high-risk growth story where spectacular fundamentals are currently overshadowed by severe technical damage and a premium valuation that demands flawless execution. The bullish analyst sentiment (multiple Buy/Outperform ratings) suggests long-term confidence, but the stock lacks a clear near-term catalyst to break its downtrend.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The stock trades at a forward P/E of 27.15x, a premium that prices in perfect execution. 2) Revenue growth remains robust at 32.2% YoY. 3) Profitability is exceptional, with a net margin of 65.5% and ROE of 40.2%. 4) The stock has corrected sharply (-25.35% in 3 months), compressing its trailing P/E from 76.4x to 21.73x, which improves the risk/reward profile but does not yet signal a clear bargain.
Risks & Conditions: The two biggest risks are failure to meet the high growth expectations embedded in its forward multiple, and continued negative momentum breaking key technical support at $89.10. This Hold would upgrade to a Buy if the stock stabilizes above support and the forward P/E compresses further towards 20x on sustained growth, or if Q1 2026 earnings demonstrate re-acceleration. It would downgrade to a Sell if revenue growth decelerates below 25% or if operating margins show sustained contraction. The stock is currently fairly valued to slightly overvalued relative to its own compressed history, but remains expensive versus sector peers, implying the market still expects superior growth.
Sign up to view all
TMDX 12-Month Price Forecast
The outlook is bifurcated. Fundamentally, TMDX is a standout performer with disruptive technology and accelerating profitability. However, technically and from a valuation perspective, the stock is under significant pressure. The base case of volatile consolidation is most likely, as the market requires time to rebuild confidence after the sharp correction. The stance is neutral because the compelling growth story is fully priced in, and the stock needs to prove it can navigate the high expectations. We would upgrade to bullish on a confirmed technical reversal above $130 coupled with sustained margin strength; a downgrade to bearish would follow a breakdown below the $89 support on weakening fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransMedics Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $94.80 and implied upside of +30.0% versus the current price.
Average Target
$94.80
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$58 - $95
Analyst target range
Analyst coverage for TMDX appears limited in the provided dataset, with only 3 analysts providing estimates for future EPS and revenue, which suggests the stock may have narrower institutional followings typical of a commercial-stage med-tech story. The consensus revenue estimate for the period is approximately $1.21 billion, with a tight range between $1.20 billion and $1.23 billion, indicating strong agreement on the near-term growth trajectory. The provided institutional ratings show a generally bullish sentiment among covering firms, with recent actions from Needham (Buy), Canaccord Genuity (Buy), Piper Sandler (Overweight), Oppenheimer (Outperform), and Evercore ISI (Outperform) against a few Hold/Neutral ratings from Stifel, JP Morgan, and Morgan Stanley. The wide dispersion in historical price targets is not provided, but the recent ratings activity shows no downgrades, suggesting analyst conviction in the long-term story remains despite recent stock price weakness.
Bulls vs Bears: TMDX Investment Factors
The investment debate for TMDX centers on the tension between its demonstrably superior fundamental performance—explosive growth, soaring profitability, and strong cash flow—and its punishing technical price action, premium valuation, and high volatility. Currently, the bearish technical momentum and valuation concerns hold stronger near-term evidence, as reflected in the stock's 25% three-month decline. However, the bullish fundamental case is compelling and suggests the sell-off may be an overreaction. The single most important factor that will resolve the thesis is whether the company can meet or exceed the high growth expectations embedded in its forward P/E of 27x in the coming quarters, thereby justifying its premium multiples and reversing the negative price trend.
Bullish
- Explosive Revenue & Profit Growth: Q4 2025 revenue grew 32.2% YoY to $160.76M, demonstrating accelerating commercial adoption. Net income surged to $105.38M with a 65.5% net margin, a dramatic improvement from $6.86M a year ago, signaling a successful transition to profitability.
- Strong & Stable Gross Margins: Gross margins have remained robust, at 58.1% in Q4 2025 and consistently in the high-50% to low-60% range. This indicates significant pricing power and cost control for its proprietary Organ Care System, a hallmark of a disruptive technology leader.
- Exceptional Capital Efficiency: The company boasts a remarkably high Return on Equity of 40.2%, reflecting extremely efficient use of shareholder capital. This is supported by strong free cash flow generation of $133.59M TTM, which now funds growth internally.
- Valuation Compression from Peaks: The trailing P/E ratio has compressed significantly to 21.73x from historical peaks of 76.4x in Q4 2024 and 39.3x in Q3 2025. This derating, while the company's fundamentals have strengthened, presents a more reasonable entry point for a high-growth story.
Bearish
- Severe Technical Downtrend & Volatility: The stock is in a pronounced downtrend, down 25.35% over the past three months and trading near 64% of its 52-week range. Its beta of 2.08 indicates it is more than twice as volatile as the market, amplifying downside risk during corrections.
- Forward P/E Expansion Raises Bar: The forward P/E of 27.15x is higher than the trailing P/E of 21.73x, indicating the market is pricing in continued high earnings growth. This creates elevated expectations; any growth deceleration could trigger multiple compression and significant price declines.
- Premium Valuation Multiples: Despite the P/E compression, valuation remains premium with a P/S ratio of 6.83x and EV/Sales of 5.76x. These multiples are likely above many medical device peers, making the stock vulnerable to sector-wide de-rating or growth disappointments.
- High Short Interest & Sentiment Risk: A short ratio of 7.77 indicates significant bearish bets against the stock. This reflects skepticism about sustaining its valuation and growth trajectory, and any negative news could fuel a sharp, short-driven sell-off.
TMDX Technical Analysis
The prevailing price trend for TMDX is a pronounced downtrend from recent highs, having declined 25.35% over the past three months and 23.97% over the past six months, despite a positive 10.57% gain over the full one-year period. The stock is currently trading at $100.01, which places it at approximately 64% of its 52-week range ($89.10 to $156.00), indicating it is closer to its yearly low than its high and suggesting the momentum from earlier gains has decisively reversed. Recent momentum is starkly negative and diverges from the longer-term uptrend, with the stock down 0.39% over the past month and down 25.35% over three months; this sharp deceleration and reversal signal a significant correction or trend change, likely driven by profit-taking or valuation concerns after the stock's previous ascent. Key technical support is at the 52-week low of $89.10, while resistance lies at the 52-week high of $156.00; a breakdown below $89.10 would signal a bearish continuation, while a recovery above the recent highs near $150 would be needed to re-establish bullish momentum. The stock's beta of 2.08 indicates it is more than twice as volatile as the broader market, which is critical for risk assessment as it amplifies both gains and losses.
Beta
2.06
2.06x market volatility
Max Drawdown
-51.5%
Largest decline past year
52-Week Range
$70-$156
Price range past year
Annual Return
-21.9%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | -30.4% | +11.4% |
| 3m | -43.7% | +8.3% |
| 6m | -38.8% | +9.4% |
| 1y | -21.9% | +31.3% |
| ytd | -40.6% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
TransMedics is on an explosive revenue growth trajectory, with Q4 2025 revenue of $160.76 million representing a 32.2% year-over-year increase, and this follows consistent sequential growth from $143.54 million in Q1 2025. The multi-quarter trend shows accelerating top-line expansion, driven by the commercial adoption of its OCS technology across transplant centers. The company has achieved significant profitability, with Q4 2025 net income of $105.38 million and a net margin of 65.5%, a dramatic improvement from the $6.86 million net income in Q4 2024. Gross margins are robust at 58.1% for the latest quarter and have been stable in the high-50% to low-60% range, indicating strong pricing power and cost control for its proprietary systems. The balance sheet and cash flow position are solid, with a strong current ratio of 7.14, a manageable debt-to-equity ratio of 0.99, and trailing twelve-month free cash flow of $133.59 million. The return on equity of 40.2% is exceptionally high, reflecting efficient use of shareholder capital, and the company's substantial cash generation now funds its growth internally, reducing financial risk.
Quarterly Revenue
$160764000.0B
2025-12
Revenue YoY Growth
+0.32%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$133589000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 21.73x, while the forward PE is 27.15x based on estimated EPS; the higher forward multiple suggests the market is pricing in expectations for continued, though potentially moderating, earnings growth. Compared to sector averages, TMDX's trailing PE of 21.7x is difficult to contextualize without a specific industry peer average, but its Price-to-Sales ratio of 6.83x and EV/Sales of 5.76x are likely at a premium to many medical device peers, justified by its superior growth profile and disruptive technology. Historically, the stock's current trailing PE of 21.7x sits well below its own historical peaks seen in recent quarters (e.g., 39.3x in Q3 2025 and 76.4x in Q4 2024), indicating a significant compression from previously lofty levels and potentially presenting a more reasonable entry point if growth fundamentals remain intact.
PE
21.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -683x~311x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: While TMDX's financials are currently strong, risks stem from its dependence on a single product, the OCS platform, for all revenue. Any disruption in adoption, reimbursement changes, or adverse clinical data could severely impact growth. The company's net margin of 65.5% in Q4 2025 is exceptionally high and may be difficult to sustain as it scales, potentially facing pricing pressure or increased sales and R&D costs. Furthermore, the forward P/E of 27.15x implies high growth expectations; a deceleration below the implied rate would trigger significant valuation compression.
Market & Competitive Risks: The primary market risk is valuation compression. Trading at a P/S of 6.83x and EV/Sales of 5.76x, TMDX carries a significant premium that is vulnerable to a broader de-rating of growth stocks, especially if interest rates remain elevated. Its beta of 2.08 means it is highly sensitive to market downturns, as evidenced by its -29.5% relative strength vs. the S&P 500 over three months. Competitively, while it is a current leader, the organ preservation space could attract new entrants or see existing competitors improve their cold storage solutions, challenging TMDX's technological edge and pricing power.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth slowdown (e.g., revenue growth falling below 20%), margin contraction due to competitive or cost pressures, and a broader market sell-off that disproportionately hits high-beta, high-multiple stocks. This could trigger analyst downgrades, intensify short-selling pressure, and lead to a re-rating towards its 52-week low. From the current price of $100.01, a decline to the 52-week low of $89.10 represents an immediate downside of approximately -11%. A more severe scenario, factoring in the stock's recent max drawdown of -37.3%, suggests a realistic worst-case loss could extend to -30% to -40% if negative catalysts align.
FAQ
The key risks are: 1) Valuation & Execution Risk: The high forward P/E of 27.15x means the stock is vulnerable if growth decelerates or margins contract. 2) Market & Volatility Risk: With a beta of 2.08, TMDX will fall more than the market in downturns, as seen in its -29.5% 3-month relative strength. 3) Product Concentration Risk: All revenue depends on the OCS platform; any clinical, regulatory, or reimbursement setback would be catastrophic. 4) Sentiment Risk: High short interest (short ratio 7.77) can fuel sharp declines on any negative news.
Our 12-month forecast outlines three scenarios. The base case (55% probability) sees the stock consolidating between $110 and $130 as it meets growth estimates but struggles with valuation. The bull case (25% probability) projects a return to the $150-$156 range on stellar execution and renewed investor enthusiasm. The bear case (20% probability) warns of a retest of the 52-week low near $89 if growth disappoints. The base case is most likely, centered on the analyst consensus revenue estimate of ~$1.21B, assuming the company executes well but the stock's multiple does not expand.
TMDX is fairly valued to slightly overvalued based on current metrics. Its trailing P/E of 21.73x is reasonable for a company with its growth and profitability profile, but the forward P/E of 27.15x indicates the market is pricing in continued premium growth. Compared to likely medical device peers, its P/S ratio of 6.83x and EV/Sales of 5.76x suggest a significant premium. The valuation implies the market expects TMDX to maintain its disruptive momentum and high margins. While not egregiously overvalued after its 25% decline, it is not clearly undervalued either, leaving little margin for error.
TMDX presents a high-risk, high-reward opportunity. For aggressive growth investors comfortable with volatility (beta of 2.08), the current pullback to $100.01 from highs near $156 offers a more attractive entry point than several months ago, especially given its robust 32.2% revenue growth and 65.5% net margin. However, it is not a 'good buy' for conservative investors, given its premium valuation (forward P/E of 27.15x) and severe recent downtrend. It could be a good buy for those who believe the company will continue to beat high expectations and that the technical damage is overdone, but it requires careful position sizing and a long-term view.
TMDX is unequivocally suited for long-term investment, with a minimum suggested holding period of 3-5 years. Its story is about transforming organ transplant therapy, a process that will take years of clinical adoption and reimbursement wins to fully play out. The stock's high beta (2.08) and lack of a dividend make it unsuitable for short-term trading or income-seeking investors. Long-term holders can potentially benefit from the underlying disruptive growth while weathering the extreme volatility inherent in commercial-stage med-tech stocks.